

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-17 (canceled)

Claim 18 (new): A method for enhancing the absorption rate of a pharmaceutically acceptable amine into the blood of a human comprising administering a stable suspension comprising (i) a pharmacologically effective dosage of a pharmaceutically acceptable amine and (ii) an effective amount of ibuprofen.

Claim 19 (new): The method of claim 18 wherein the amine is pseudoephedrine.

Claim 20 (new): The method of claim 18 wherein the enhanced absorption is indicated by AUC 1 H (early drug exposure) that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 21 (new): The method of claim 18 wherein the enhanced absorption is indicated by AUC 2 H (early drug exposure) that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 22 (new): The method of claim 18 wherein the enhanced absorption is indicated by a C MAX (maximum or peak concentration) that is at least about 10% greater than the C MAX of the same amine from a single-ingredient liquid.

Claim 23 (new): The method of claim 18 wherein the amine is provided in a range from about 15 mg to about 60 mg per dosage unit.

Claim 24 (new): The method of claim 18 wherein the ibuprofen is provided in an amount of from about 40 mg to about 800 mg per dosage unit.

Claim 25 (new): The method of claim 23 wherein the ibuprofen is provided in an amount of from about 40 mg to about 800 mg per dosage unit.

Claim 26 (new): The method of claim 18 wherein the amine is provided at about 15 milligrams per 5 mL and the ibuprofen is provided at about 100 milligrams per 5 mL.

Claim 27 (new): The method of claim 18 wherein the human is a child.

Claim 28 (new): A stable suspension comprising (i) a pharmacologically effective amount of a pharmaceutically acceptable amine and (ii) a pharmacologically effective amount of a nonsteroidal anti-inflammatory drug.

Claim 29 (new): The stable suspension of claim 28, wherein the suspension provides an enhanced absorption rate of the amine into the blood of a human compared with a corresponding suspension comprising the amine but not the nonsteroidal anti-inflammatory drug.

Claim 30 (new): The suspension of claim 28, wherein the nonsteroidal anti-inflammatory drug is ibuprofen.

Claim 31 (new): The suspension of claim 29, wherein the nonsteroidal anti-inflammatory drug is ibuprofen.

Claim 32 (new): The suspension of claim 30, wherein the amine is pseudoephedrine.

Claim 33 (new): The suspension of claim 31, wherein the amine is pseudoephedrine.

Claim 34 (new): The suspension of claim 30 wherein the enhanced absorption is indicated by AUC 1 H (early drug exposure) that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 35 (new): The suspension of claim 30 wherein the enhanced absorption is indicated by AUC 2 H (early drug exposure) that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 36 (new): The suspension of claim 30 wherein the enhanced absorption is indicated by a C MAX (maximum or peak concentration) that is at least about 10% greater than the C MAX of the same amine from a single-ingredient liquid.

Claim 37 (new): The suspension of claim 30 wherein the amine is provided in a range from about 15 mg to about 60 mg per dosage unit.

Claim 38 (new): The suspension of claim 30 wherein the ibuprofen is provided in an amount of from about 40 mg to about 800 mg per dosage unit.

Claim 39 (new): The suspension of claim 37 wherein the ibuprofen is provided in an amount of from about 40 mg to about 800 mg per dosage unit.

Claim 40 (new): The suspension of claim 32 wherein the pseudoephedrine hydrochloride is provided at about 15 milligrams per 5 mL and the ibuprofen is provided at about 100 milligrams per 5 mL.

Claim 41 (new): The suspension of claim 30 wherein the human is a child.

Claim 42 (new): The suspension of claim 30, wherein the suspension further comprises xanthan gum, pregelatinized starch, polyoxyethylene sorbitan monooleate and a taste masking agent selected from the group consisting of sugar, sweet polyhydric alcohol, cyclamates, aspartame, sucralose saccharin, flavoring agents and mixtures thereof.